Why is Ionis Pharmaceuticals stock down 8.6% today?

Traders Union
All News
Financial News
Ionis Pharmaceuticals slides 8.6% today

Highlights

Ionis Pharmaceuticals shares fell 8.6% after its AstraZeneca-partnered Wainua failed a Phase 3 trial for ATTR-CM, missing its main clinical endpoint.
Investor sentiment remains cautious as the trial setback raises concerns over Ionis's funding flexibility and pipeline negotiation strength, despite ongoing revenue from Spinraza.
Technically, the stock is deeply oversold, trading below major averages with near-term consolidation expected between $58.37 and $64.10 and a forecasted range of $47.42 to $70.06.

Investor confidence falls as Wainua trial disappoints and funding risks rise

Ionis Pharmaceuticals experienced a significant setback after a late-stage Phase 3 clinical trial for Wainua, its drug developed in partnership with AstraZeneca, failed to achieve its main goal of reducing cardiovascular deaths and recurring heart problems in patients with ATTR-CM. This development led to a notable drop in the company's share price, reflecting investor concerns over the impact of the trial results on Ionis’ funding flexibility and bargaining power for future pipeline developments. Ionis retains a strong position in RNA-based therapies, with its spinal muscular atrophy drug Spinraza, marketed by Biogen, continuing to be recognized as a major commercial RNA-based treatment.

Anton Kharitonov, expert at Traders Union, sees Ionis Pharmaceuticals under severe pressure following the failed Phase 3 trial of Wainua. He notes the stock has sunk below all major moving averages, highlighting deep technical and sentiment-driven weakness. Oversold readings across momentum indicators show exhaustion from sellers, yet no sign of sustained buyer interest. Kharitonov is concerned that the setback undermines Ionis’ funding power and future pipeline confidence despite Spinraza’s commercial strength. "Until the company regains positive clinical momentum or clears $64.1, any rebound attempts are likely to fail," he warns.

Viktoras Karapetjanc, expert at Traders Union, acknowledges the disappointing trial result but holds a constructive view on Ionis Pharmaceuticals’ pipeline and partnerships. He believes the firm’s RNA-based therapeutic expertise and ongoing collaborations continue to offer compelling long-term opportunities. Karapetjanc emphasizes that strong volatility can reveal favorable entry points for patient investors. "I expect renewed upside as the market refocuses on Ionis’ broader innovation story and not just one clinical setback," he says.

Jainam Mehta, market strategist, observes heightened volatility and a sharp technical breakdown in Ionis Pharmaceuticals. He sees a risk of a further drop toward $47.42 if bearish momentum persists. Still, deeply oversold readings suggest the potential for a snapback rally should sentiment shift or buyers emerge at support. "Traders may find tactical opportunities on mean-reversion plays if the price stabilizes near $58.37," he notes.

Deep oversold readings as price nears support amid weak trend signals

Ionis Pharmaceuticals remains under pressure, trading well below its 20-day, 50-day, and 200-day moving averages at $77.15, $75.93, and $76.11. This action signals ongoing bearish momentum across all timeframes. The near-term support is at $58.37, while resistance stands at $64.1, with key longer-term resistance levels and the Ichimoku Kijun at $75.43 confirming the negative trend. Momentum indicators deepen the bearish outlook: RSI at 31.14, Stochastic RSI at 0, and CCI at -194.89 all show strong oversold conditions. The MACD reads as "Strong Buy," hinting at possible reversal, but the ADX at 19.17 signals a weak trend overall. BBP at -8.12 confirms seller dominance. Intraday, the price has sharply declined to $58.74, close to session lows with heightened volatility of 9.87%.

Previously, analysts noted that Ionis Pharmaceuticals had maintained a cautiously optimistic technical outlook, with investors closely watching for sustained support as an indicator of near-term direction. The latest clinical setback and pronounced shift into oversold territory mark a significant change in sentiment, making the $58.37 support a critical level to monitor for signs of either stabilization or further downside risk.

Source of Data: IONS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.